We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Industry watchers were worried about Bayer neglecting its healthcare division after the company chased down a megamerger with agrochemical giant Monsanto. But that deal hasn’t even closed yet, and healthcare sales are already showing cause for concern.